CDK8/19-IN-2_product_DataBase

Bioactivity	CDK8/19-IN-2 (compound 12) is an orally active and potent cyclin-dependent kinase 8/19 (CDK8 and CDK19) inhibitor, with IC50 values of 2.08 and 2.49 nM, respectively. CDK8/19-IN-2 can be used for acute myeloid leukemia (AML), breast cancer, and lymphoma research[1].
Invitro	CDK8/19-IN-2 (compound 12) 抑制 MV4-11 人 AML 细胞增殖 (IC50 = 5.719 nM)[1]。CDK8/19-IN-2 (0-10 μM) 剂量依赖性地降低 STAT1 在丝氨酸 727 上的磷酸化 (p-STAT1 S727)[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> CDK8/19-IN-2 相关抗体:
In Vivo	CDK8/19-IN-2 (compound 12) (3-10 mg/kg，灌胃口服，每天一次)可抑制肿瘤生长[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS	3024381-54-9
Formula	C17H20Br2F2N4O
Molar Mass	494.17
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Xu J, et al. Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer. J Med Chem. 2024 May 23;67(10):8161-8171.

PeptideDB